Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors —protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)
This study addresses the current gap in the evidence base regarding the combination of these two drugs, which is particularly relevant given the American Diabetes Association and European Association for the Study of Diabetes guidelines recommending their combined use for patients with obesity, type 2 diabetes, and chronic kidney disease who do not achieve metabolic control with either drug alone.Trial registrationClinicalTrials.gov Identifier: NCT05390307 Trial registration date - 25th May 2022 (Source: Trials)
Source: Trials - February 16, 2024 Category: Research Source Type: clinical trials
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Conditions: Diabetes Mellitus, Type 2 Interventions: Drug: Retatrutide; Drug: Semaglutide Sponsors: Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Conditions: Type2 Diabetes Mellitus Interventions: Drug: Exendin-4 Fc fusion protein injection(1.2mg ）; Drug: Exendin-4 Fc fusion protein injection（2.4mg）; Drug: Dulaglutide; Drug: Metformin Sponsors: Beijing Dongfang Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Feasibility of Kanasina Gulabi, a Pilot Peer Support Intervention for Young Adults With Type 2 Diabetes in Mysore District, South India
Conditions: Type 2 Diabetes; Quality of Life; Depression; Stigma, Social; Behavior, Health Interventions: Behavioral: Kanasina Gulabi Sponsors: Duke University; Public Health Research Institute of India Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Phase 3 Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: TG103; Drug: Placebo Sponsors: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2 Interventions: Device: Duodenal Mucosal Resurfacing (DMR) Sponsors: Fractyl Health Inc. Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
Conditions: Type 2 Diabetes Interventions: Drug: GZR18; Drug: Semaglutide Sponsors: Gan and Lee Pharmaceuticals, USA Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)
Conditions: Type 2 Diabetes Interventions: Drug: GZR18; Other: Placebo Sponsors: Gan and Lee Pharmaceuticals, USA Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
Conditions: Type 2 Diabetes Mellitus; Susceptibility, Genetic Interventions: Drug: GLP-1 receptor agonist; Drug: responders group and nonresponders group Sponsors: The Affiliated Hospital of Xuzhou Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
A Study of RAY1225 in Participants With Type 2 Diabetes
Conditions: T2DM (Type 2 Diabetes Mellitus) Interventions: Drug: RAY1225; Drug: Placebo Sponsors: Guangdong Raynovent Biotech Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: Exendin-4 Fc fusion protein injection; Drug: Exendin-4 Fc fusion protein injection; Drug: Placebo Sponsors: Beijing Dongfang Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Effects of Antipsychotics on Brain Insulin Action in Females
Conditions: Insulin Resistance; Menstrual Cycle; Type 2 Diabetes; Antipsychotics Interventions: Drug: Olanzapine 2.5Mg Oral Tablet; Drug: Placebo; Drug: Insulin Lispro 100 UNT/ML; Drug: Saline Sponsors: Centre for Addiction and Mental Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)
Conditions: Influenza; Vaccine Reaction; Diabetes Mellitus; Chronic Kidney Diseases Interventions: Drug: Trivalent Influenza Vaccine Sponsors: Universitas Padjadjaran; Biofarma; Universiti Sains Malaysia Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Implementing Scalable, PAtient-centered Team-based Care for Adults With Type 2 Diabetes and Health Disparities (iPATH)
Conditions: Diabetes Mellitus, Type 2 Interventions: Other: iPATH implementation approach Sponsors: Stanford University; Ohio State University; Harvard School of Public Health (HSPH); Impactivo, LLC. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects
Conditions: Diabetes Mellitus, Type 2; Overweight Interventions: Drug: Exendin-4 Fc fusion protein (JY09) injection; Drug: Metformin Hydrochloride tablet; Drug: Rosuvastatin calcium tablets; Drug: Digoxin tablet Sponsors: Beijing Dongfang Biotech Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
